Cadence Pharmaceuticals, (FRA:QEW) Interest Expense : €-3.36 Mil (TTM As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cadence Pharmaceuticals,'s interest expense for the three months ended in Dec. 2013 was € -0.83 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2013 was €-3.36 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cadence Pharmaceuticals,'s Operating Income for the three months ended in Dec. 2013 was € -2.19 Mil. Cadence Pharmaceuticals,'s Interest Expense for the three months ended in Dec. 2013 was € -0.83 Mil. Cadence Pharmaceuticals, did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cadence Pharmaceuticals, Interest Expense Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Interest Expense Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Interest Expense

Get a 7-Day Free Trial

-0.78

-1.62

-3.36

-3.39

-3.26

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Interest Expense	Get a 7-Day Free Trial															-0.85	-0.85	-0.84	-0.84	-0.83

Cadence Pharmaceuticals, Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.36 Mil.

Cadence Pharmaceuticals, (FRA:QEW) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cadence Pharmaceuticals,'s Interest Expense for the three months ended in Dec. 2013 was €-0.83 Mil. Its Operating Income for the three months ended in Dec. 2013 was €-2.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2013 was €13.53 Mil.

Cadence Pharmaceuticals,'s Interest Coverage for the quarter that ended in Dec. 2013 is calculated as

Cadence Pharmaceuticals, did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines